April 2019 Drug Utilization Review Board Meeting Summary

Information posted May 24, 2019

The Texas Drug Utilization Review (DUR) Board met April 26, 2019, to make recommendations for Medicaid clinical prior authorizations and the Preferred Drug List (PDL). A summary of this meeting is now available on the Texas Vendor Drug Program (VDP) website.

Clinical Prior Authorization Reminders

- Clinical prior authorizations for traditional Medicaid and Medicaid managed care organizations (MCOs) may differ. The Pharmacy Clinical Prior Authorization Assistance Chart identifies each MCO’s prior authorizations and how they relate to the prior authorizations for traditional Medicaid.

- Each MCO pharmacy website must include a list of the clinical prior authorizations that are active for that MCO.

Preferred Drug List Reminders

- All PDL recommendations are pending until the Texas Health and Human Services Commission (HHSC) executive commissioner releases a final decision. HHSC-approved decisions from the January and April 2019 board meetings will be incorporated into the PDL published in July 2019.

- Prescribing providers must use the Medicaid formulary and PDL.

- MCOs must adhere to the Medicaid formulary and PDL. MCO staff members should check the Medicaid drug formulary prior to checking the PDL to ensure that the drug is active. If it appears on both the Medicaid formulary and PDL, the drug is considered active and requires prior authorization.

About the Texas DUR Board

The next board meeting is scheduled for Friday, July 26, 2019. Board members meet quarterly in Austin to recommend outpatient prescription drugs for Texas Medicaid. The schedule of upcoming meetings, instructions on how to submit written materials to the board, and directions about publicly testifying before the board are available on the VDP website.